Business Description
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Total Employee Number:
1,371Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.47 | |||||
Equity-to-Asset | -0.18 | |||||
Debt-to-Equity | -0.15 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.35 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.5 | |||||
3-Year EBITDA Growth Rate | 19.3 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 13.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 23.43 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.02 | |||||
Quick Ratio | 1.85 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 166.54 | |||||
Days Sales Outstanding | 67.02 | |||||
Days Payable | 129.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.2 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.52 | |||||
Operating Margin % | -83.78 | |||||
Net Margin % | -90.92 | |||||
EBITDA Margin % | -75.04 | |||||
FCF Margin % | -75.4 | |||||
OCF Margin % | -73.77 | |||||
ROA % | -45.88 | |||||
ROIC % | -77.22 | |||||
3-Year ROIIC % | 222.51 | |||||
ROC (Joel Greenblatt) % | -214.69 | |||||
ROCE % | -53.63 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.94 | |||||
EV-to-EBIT | -4.69 | |||||
EV-to-EBITDA | -5.01 | |||||
EV-to-Revenue | 3.76 | |||||
EV-to-Forward-Revenue | 5.2 | |||||
EV-to-FCF | -5.19 | |||||
Price-to-GF-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | -21.32 | |||||
FCF Yield % | -16.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 12,284.607 | ||
| EPS (TTM) (MXN) | -111.709 | ||
| Beta | -0.062 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 1150.56 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 1150.56 - 1150.56 | ||
| Shares Outstanding (Mil) | 98.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ultragenyx Pharmaceutical Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 112 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 21 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 1,150.56 (+0.00%) | ||
| General meeting for 2026 | 2026-05-14 08:30 | 1,150.56 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 14:20 | 1,150.56 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 17:00 | 1,150.56 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1,150.56 (+0.00%) | ||
| Leerink Partners Global Biopharma Conference | 2026-03-11 10:00 | 1,150.56 (+0.00%) |
Show
Entries
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(MEX:RARE)'s stock price today?
The current price of MEX:RARE is MXN1150.56. The 52 week high of MEX:RARE is MXN1150.56 and 52 week low is MXN1150.56.
When is next earnings date of Ultragenyx Pharmaceutical Inc(MEX:RARE)?
The next earnings date of Ultragenyx Pharmaceutical Inc(MEX:RARE) is 2026-08-05 Est..
Does Ultragenyx Pharmaceutical Inc(MEX:RARE) pay dividends? If so, how much?
Ultragenyx Pharmaceutical Inc(MEX:RARE) does not pay dividend.
Press Release
Articles on Ultragenyx Pharmaceutical Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers